471 related articles for article (PubMed ID: 34391699)
1. Precision therapy for RET-altered cancers with RET inhibitors.
Thein KZ; Velcheti V; Mooers BHM; Wu J; Subbiah V
Trends Cancer; 2021 Dec; 7(12):1074-1088. PubMed ID: 34391699
[TBL] [Abstract][Full Text] [Related]
2. Precious Gene: The Application of RET-Altered Inhibitors.
Gou Q; Gan X; Li L; Gou Q; Zhang T
Molecules; 2022 Dec; 27(24):. PubMed ID: 36557971
[TBL] [Abstract][Full Text] [Related]
3. Precision Targeted Therapy with BLU-667 for
Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
[TBL] [Abstract][Full Text] [Related]
4. RET fusions in solid tumors.
Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
[TBL] [Abstract][Full Text] [Related]
5. Progress and challenges in RET-targeted cancer therapy.
Hu X; Khatri U; Shen T; Wu J
Front Med; 2023 Apr; 17(2):207-219. PubMed ID: 37131086
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
Lin JJ; Liu SV; McCoach CE; Zhu VW; Tan AC; Yoda S; Peterson J; Do A; Prutisto-Chang K; Dagogo-Jack I; Sequist LV; Wirth LJ; Lennerz JK; Hata AN; Mino-Kenudson M; Nardi V; Ou SI; Tan DS; Gainor JF
Ann Oncol; 2020 Dec; 31(12):1725-1733. PubMed ID: 33007380
[TBL] [Abstract][Full Text] [Related]
7. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
Subbiah V; Shen T; Terzyan SS; Liu X; Hu X; Patel KP; Hu M; Cabanillas M; Behrang A; Meric-Bernstam F; Vo PTT; Mooers BHM; Wu J
Ann Oncol; 2021 Feb; 32(2):261-268. PubMed ID: 33161056
[TBL] [Abstract][Full Text] [Related]
8. Predictive molecular pathology in metastatic thyroid cancer: the role of
Nacchio M; Pisapia P; Pepe F; Russo G; Vigliar E; Porcelli T; Luongo C; Iaccarino A; Pagni F; Salvatore D; Troncone G; Malapelle U; Bellevicine C
Expert Rev Endocrinol Metab; 2022 Mar; 17(2):167-178. PubMed ID: 35404189
[TBL] [Abstract][Full Text] [Related]
9. RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.
Hamidi S; Hu MI
Ann Endocrinol (Paris); 2024 Apr; 85(2):118-126. PubMed ID: 38342224
[TBL] [Abstract][Full Text] [Related]
10. Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions.
Zheng H; Chen ZS; Li J
Drugs Today (Barc); 2021 Oct; 57(10):621-629. PubMed ID: 34713870
[TBL] [Abstract][Full Text] [Related]
11. RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges.
Servetto A; Esposito D; Ferrara R; Signorelli D; Belli S; Napolitano F; Santaniello A; Ciciola P; Formisano L; Bianco R
Biochim Biophys Acta Rev Cancer; 2022 Nov; 1877(6):188810. PubMed ID: 36202311
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic strategies in RET gene rearranged non-small cell lung cancer.
Drusbosky LM; Rodriguez E; Dawar R; Ikpeazu CV
J Hematol Oncol; 2021 Mar; 14(1):50. PubMed ID: 33771190
[TBL] [Abstract][Full Text] [Related]
13. An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present).
Acharya B; Frett B
Expert Opin Ther Pat; 2022 Oct; 32(10):1067-1077. PubMed ID: 36198171
[TBL] [Abstract][Full Text] [Related]
14. Selective RET kinase inhibition for patients with RET-altered cancers.
Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A
Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274
[TBL] [Abstract][Full Text] [Related]
15. RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives.
Addeo A; Miranda-Morales E; den Hollander P; Friedlaender A; O Sintim H; Wu J; Mani SA; Subbiah V
Pharmacol Ther; 2023 Feb; 242():108344. PubMed ID: 36632846
[TBL] [Abstract][Full Text] [Related]
16. Targeting RET alterations in non-small cell lung cancer.
Nishikawa G; Klein MA
Curr Probl Cancer; 2024 Apr; 49():101074. PubMed ID: 38494387
[TBL] [Abstract][Full Text] [Related]
17. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Solomon BJ; Tan L; Lin JJ; Wong SQ; Hollizeck S; Ebata K; Tuch BB; Yoda S; Gainor JF; Sequist LV; Oxnard GR; Gautschi O; Drilon A; Subbiah V; Khoo C; Zhu EY; Nguyen M; Henry D; Condroski KR; Kolakowski GR; Gomez E; Ballard J; Metcalf AT; Blake JF; Dawson SJ; Blosser W; Stancato LF; Brandhuber BJ; Andrews S; Robinson BG; Rothenberg SM
J Thorac Oncol; 2020 Apr; 15(4):541-549. PubMed ID: 31988000
[TBL] [Abstract][Full Text] [Related]
18. Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.
Wang ZX; Li QQ; Cai J; Wu JZ; Wang JJ; Zhang MY; Wang QX; Tong ZJ; Yang J; Wei TH; Zhou Y; Dai WC; Ding N; Leng XJ; Sun SL; Xue X; Yu YC; Yang Y; Li NG; Shi ZH
J Med Chem; 2024 Mar; 67(6):4346-4375. PubMed ID: 38484122
[TBL] [Abstract][Full Text] [Related]
19. Hallmarks of RET and Co-occuring Genomic Alterations in
Adashek JJ; Desai AP; Andreev-Drakhlin AY; Roszik J; Cote GJ; Subbiah V
Mol Cancer Ther; 2021 Oct; 20(10):1769-1776. PubMed ID: 34493590
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
Sun F; McCoach CE
Curr Treat Options Oncol; 2021 Jun; 22(8):72. PubMed ID: 34165651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]